Literature DB >> 12224515

The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol.

F J van der Wal1, M Kikkert, E Wiertz.   

Abstract

Over millions of years of coevolution with their hosts, viruses have developed highly effective strategies to elude the host immune system. The degradation of major histocompatibility complex (MHC) class I heavy chains by human cytomegalovirus (HCMV) is an example of this. Two HCMV proteins, US2 and US11, target newly synthesized MHC class I heavy chains for destruction via a pathway that involves ubiquitin-dependent retrograde transport, or "dislocation", of the heavy chains from the ER to the cytosol, where the proteins are degraded by proteasomes. In this review, US2- and US11-mediated degradation of MHC class I heavy chains is discussed in relation to data concerning the degradation of other ER luminal proteins. A new, unified model for translocon-facilitated dislocation and degradation of MHC class I heavy chains is presented.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224515     DOI: 10.1007/978-3-642-59421-2_3

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  20 in total

Review 1.  The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum.

Authors:  Kunio Nakatsukasa; Jeffrey L Brodsky
Journal:  Traffic       Date:  2008-02-24       Impact factor: 6.215

Review 2.  CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination.

Authors:  Klaus Früh; Louis Picker
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

3.  Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity.

Authors:  Nicole Gudleski-O'Regan; Todd M Greco; Ileana M Cristea; Thomas Shenk
Journal:  Cell Host Microbe       Date:  2012-07-19       Impact factor: 21.023

4.  Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus.

Authors:  Scott G Hansen; Colin J Powers; Rebecca Richards; Abigail B Ventura; Julia C Ford; Don Siess; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Louis J Picker; Klaus Früh
Journal:  Science       Date:  2010-04-02       Impact factor: 47.728

5.  Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions.

Authors:  Luis V Nobre; Katie Nightingale; Benjamin J Ravenhill; Robin Antrobus; Lior Soday; Jenna Nichols; James A Davies; Sepehr Seirafian; Eddie Cy Wang; Andrew J Davison; Gavin Wg Wilkinson; Richard J Stanton; Edward L Huttlin; Michael P Weekes
Journal:  Elife       Date:  2019-12-24       Impact factor: 8.140

6.  Retrotranslocation of the chaperone calreticulin from the endoplasmic reticulum lumen to the cytosol.

Authors:  Nima Afshar; Ben E Black; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

7.  Degrons at the C terminus of the pathogenic but not the nonpathogenic hantavirus G1 tail direct proteasomal degradation.

Authors:  Nandini Sen; Adrish Sen; Erich R Mackow
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

8.  Viral mediated tethering to SEL1L facilitates ER-associated degradation of IRE1.

Authors:  Florian Hinte; Jendrik Müller; Wolfram Brune
Journal:  J Virol       Date:  2021-01-20       Impact factor: 5.103

9.  Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes.

Authors:  Naeem Khan; Rachel Bruton; Graham S Taylor; Mark Cobbold; Thomas R Jones; Alan B Rickinson; Paul A H Moss
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  Antigen processing and remodeling of the endosomal pathway: requirements for antigen cross-presentation.

Authors:  Ewoud Bernardus Compeer; Thijs Willem Hendrik Flinsenberg; Susanna Geertje van der Grein; Marianne Boes
Journal:  Front Immunol       Date:  2012-03-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.